Our verdict is Likely benign. Variant got -1 ACMG points: 2P and 3B. PM1BP4_ModerateBP6
The NM_000251.3(MSH2):āc.1378A>Gā(p.Met460Val) variant causes a missense change. The variant allele was found at a frequency of 0.0000376 in 1,596,962 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. M460I) has been classified as Likely benign.
MSH2 (HGNC:7325): (mutS homolog 2) This locus is frequently mutated in hereditary nonpolyposis colon cancer (HNPCC). When cloned, it was discovered to be a human homolog of the E. coli mismatch repair gene mutS, consistent with the characteristic alterations in microsatellite sequences (RER+ phenotype) found in HNPCC. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]
Verdict is Likely_benign. Variant got -1 ACMG points.
PM1
In a hotspot region, there are 5 aminoacids with missense pathogenic changes in the window of +-8 aminoacids around while only 7 benign, 17 uncertain in NM_000251.3
BP4
Computational evidence support a benign effect (MetaRNN=0.19934508).
BP6
Variant 2-47445649-A-G is Benign according to our data. Variant chr2-47445649-A-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 237367.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=5, Uncertain_significance=2, Benign=1}.
Likely benign, criteria provided, single submitter
clinical testing
GeneDx
Mar 28, 2019
This variant is associated with the following publications: (PMID: 30441849) -
Likely benign, criteria provided, single submitter
clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano
Aug 23, 2023
- -
Hereditary cancer-predisposing syndrome Benign:2
Likely benign, criteria provided, single submitter
clinical testing
Color Diagnostics, LLC DBA Color Health
Dec 13, 2022
- -
Benign, criteria provided, single submitter
clinical testing
Ambry Genetics
Apr 11, 2022
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Breast and/or ovarian cancer Uncertain:1
Uncertain significance, criteria provided, single submitter
clinical testing
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario
Feb 01, 2022
- -
Lynch syndrome 1 Uncertain:1
Uncertain significance, criteria provided, single submitter
clinical testing
Neuberg Centre For Genomic Medicine, NCGM
-
The missense variant c.1378A>G (p.Met460Val) in MSH2 gene has not been reported previously as a pathogenic variant nor as a benign variant, to our knowledge. This variant has been reported to the ClinVar database with conflicting interpretations of pathogenicity. This variant is present in the gnomAD database with a frequency of 0.008%. The amino acid Met at position 460 is changed to a Val changing protein sequence and it might alter its composition and physico-chemical properties. There is a small physicochemical difference between methionine and valine, which is not likely to impact secondary protein structure as these residues share similar properties. The p.M460V missense variant is predicted to be damaging by both SIFT and PolyPhen2. The amino acid change p.Met460Val in MSH2 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. For these reasons, this variant has been classified as Uncertain Significance -
Lynch syndrome Benign:1
Likely benign, criteria provided, single submitter
clinical testing
All of Us Research Program, National Institutes of Health
Nov 30, 2023
This missense variant replaces methionine with valine at codon 460 of the MSH2 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with ovarian cancer (PMID: 30441849). This variant has been identified in 20/250266 chromosomes (19/30482 South Asian chromosomes) in the general population by the Genome Aggregation Database (gnomAD). The elevated variant allele frequency in the general population indicates that this variant may not be disease-causing. However, additional studies are necessary to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -